Drug
Edp239
Edp239: highest development phase Phase 1, developed by Enanta Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP239 NCT01856426 | Phase 1 | Hepatitis C |
Latest
No recent events.
Follow Edp239 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.